How is Rozebalamin (methylcobalamin) used?

Rozebalamin (methylcobalamin) is used to treat amyotrophic lateral sclerosis (ALS). Its use and dosage must strictly follow the doctor's instructions. The drug is administered by intramuscular injection, with the recommended dose per injection being 50mg (i.e. using 2 vials), and injections are required twice a week. The intervals between injections must be at least 11 days, for example if the first injection is given on Monday, the second injection should be scheduled for Thursday.

When starting to use Rozebalamin, patients should take the first injection under the guidance of a doctor or health care provider, and it must be done in an environment equipped with the required medical facilities. When using the medication for the first time, patients need detailed training on how to use the medication and syringe correctly. For patients who need to self-inject at home, medical staff will assess the patient's condition and provide necessary support and training after ensuring that the patient can self-administer correctly.

In order to ensure the effectiveness and safety of the drug, patients must strictly abide by the usage regulations when self-injecting at home. Medical staff should provide complete injection operation training to help patients master correct injection techniques. Patients or their family members must understand the correct storage method and use time of drugs, especially since drugs are sensitive to light. Drugs must be stored away from light, and dissolved drugs should be used within 60 minutes.

If the patient misses the scheduled injection time, he should make up for the injection as soon as possible, but he can only inject at most 2 bottles at a time, and do not inject more than the prescribed dose at one time. If an abnormal reaction at the injection site occurs or other uncomfortable symptoms occur, the patient should stop the injection immediately and contact medical staff to deal with possible side effects.

xa0

References:

[1]https://pins.japic.or.jp/pdf/newPINS/00071540.pdf

[2]https://www.eisai.com/news/2024/news202487.html